Clinical Study
A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis
Table 1
Baseline characteristics of patients in infliximab group and tacrolimus group.
| | | Infliximab group | Tacrolimus group | value | | | () | () |
| | Sex | | | 0.93 | | Men (%) | 31 (64.6) | 30 (63.8) | | | Female (%) | 17 (35.4) | 17 (36.2) | | | Age at diagnosis (y) | 24 (12–59) | 30 (12–67) | 0.041 | | Age at start of the treatment (y) | 31 (14–67) | 34 (15–70) | 0.25 | | Disease duration at the treatment (y) | 4 (0.6–32) | 3 8 (0.1–18) | 0.031 | | Disease extension | | | 0.72 | | Left-sided colitis (%) | 17 (35.4) | 15 (31.9) | | | Extensive colitis (%) | 31 (64.6) | 32 (68.1) | | | Response to corticosteroids | | | 0.003 | | Steroids refractory (%) | 17 (35.4) | 31 (66.0) | | | Steroids dependence (%) | 26 (54.2) | 16 (34.0) | | | Others (%) | 5 (10.4) | 0 (0) | | | Thiopurine-naïve (%) | 22 (45.8) | 38 (80.9) | 0.0004 | | Previous IFX treatment | — | 5 (10.6) | — | | Previous Tac treatment | 14 (29.2) | — | — | | Laboratory data at start of the treatment | | | | | Hemoglobin (g/dL) | 12.6 (8.6–17.5) | 10.9 (7.2–15) | 0.018 | | Albumin (g/dL) | 3.8 (2.6–4.8) | 3.1 (1.9–4.5) | <0.001 | | C-reactive protein (mg/dL) | 0.4 (0.1–23.1) | 1 (0.1–7.5) | 0.01 | | Disease activity index at start of the treatment | | | | | CAI | 7 (2–19) | 9 (4–16) | 0.006 | | EI | 8 (5–12) | 8 (3–12) | 0.005 |
|
|
Data are presented as median (range) or number (%).
CAI, Clinical Activity Index; EI, Endoscopic Index.
|
